Conflict-of-interest policies protect docs from big pharma influence
- PDF / 131,568 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 4 Downloads / 199 Views
supports findings Results from a second US study published in the BMJ support these findings, showing that exposure to a policy to restrict the receipt of gifts from the pharmaceutical industry at US medical schools can reduce prescribing of newly marketed psychotropic medications.2 The researchers examined prescribing patterns for three newly introduced and marketed psychotropic medications over older alternatives within the same drug class: lisdexamfetamine [Vyvanse], a stimulant; paliperidone [Invega], an antipsychotic; and desvenlafaxine [Pristiq], an antidepressant. Prescribing patterns of physicians attending one of the 14 medical schools with an active gift-restriction policy in place were compared with those of physicians who were not exposed to such a policy. Physicians who were exposed to a gift-restriction policy during medical training were significantly less likely to prescribe lisdexamfetamine over older stimulants (adjusted odds ratio [OR] 0.44; 95% CI 0.22, 0.88) and significantly less likely to prescribe paliperidone over older antipsychotics (adjusted OR 0.25; 0.07, 0.85), compared with physicians who were not exposed to such a policy. In contrast, exposure to a gift-restriction policy during medical training was not associated with differential prescribing of desvenlafaxine. 1. Epstein AJ, et al. Does Exposure to Conflict of Interest Policies in Psychiatry Residency Affect Antidepressant Prescribing? Medical Care 51: 199-203, No. 2, 2 Feb 2013. Available from: URL: http://dx.doi.org/10.1097/ MLR.0b013e318277eb19. 2. King M, et al. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ : 31 Jan 2013. Available from: URL: http://www.bmj.com/content/346/ bmj.f264. 801085649
1173-5503/10/0671-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 9 Feb 2013 No. 671
1
Data Loading...
